Related Experiment Video
Updated: Sep 17, 2025
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysis
Bryce Montané1, Shiyang Zhang2, Jonathan D Wolfe3
1Division of General Medicine and Geriatrics, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri (B.M., B.F.G.).
Insights
Catheter ablation for atrial fibrillation reduces long-term stroke and mortality risks. However, it may increase early stroke risk, while surgical ablation benefits are uncertain beyond stroke reduction.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Outcomes Research
Background:
- Atrial fibrillation ablation aims to restore normal heart rhythm.
- The impact of ablation on long-term clinical outcomes remains unclear.
Purpose of the Study:
- To evaluate the effect of catheter and surgical ablation on ischemic stroke risk occurring more than 30 days post-procedure.
- To assess the impact of ablation on other clinical outcomes, including mortality and heart failure hospitalizations.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials comparing ablation (catheter or surgical) with medical therapy.
- Searched multiple databases from 1987 to 2025, including bridge searches.
- Dual independent data extraction and risk-of-bias assessment were performed.
Main Results:
- Catheter ablation significantly reduced risks for ischemic stroke after 30 days (RR 0.63), mortality (RR 0.73), and heart failure hospitalizations (RR 0.68).
- Catheter ablation was associated with an increased risk of early ischemic stroke (at or before 30 days).
- Surgical ablation reduced risks for ischemic stroke (RR 0.54) and all-cause stroke, but its benefit for mortality and heart failure hospitalization was uncertain.
Conclusions:
- Catheter ablation is effective in reducing long-term risks of ischemic stroke, mortality, and heart failure hospitalizations.
- Surgical ablation shows a clear benefit in reducing stroke risk, with uncertain benefits for other outcomes.
- Further research may be needed to clarify the overall risk-benefit profile of different ablation strategies.
Background:
Ablation of atrial fibrillation can restore normal heart rhythm, but its effect on clinical outcomes is uncertain.
Purpose:
To determine the effect of ablation on ischemic stroke at more than 30 days (primary outcome).
Data Sources:
Search of 9 databases without language restrictions from 1 January 1987 to 13 September 2024, and bridge search of 2 databases to 1 May 2025.
Study Selection:
Randomized controlled trials of catheter or surgical ablation versus no ablation that had at least 1 month of follow-up and reported stroke and/or mortality.
Data Extraction:
Dual independent data extraction and risk-of-bias assessment.
Data Synthesis:
Compared with medical therapy, catheter ablation reduced risks for ischemic stroke after 30 days (relative risk [RR], 0.63 [95% CI, 0.43 to 0.92]), mortality (RR, 0.73 [CI, 0.60 to 0.88]), and heart failure (HF) hospitalization (RR, 0.68 [CI, 0.55 to 0.85]). However, catheter ablation increased the RR for ischemic stroke at or before 30 days (6.81 [CI, 1.56 to 29.8]) such that the RRs were 0.77 (CI, 0.55 to 1.09) for any ischemic stroke and 0.77 (CI, 0.57 to 1.05) for all strokes. Surgical ablation reduced the RRs for ischemic stroke (0.54 [CI, 0.34 to 0.86]) and stroke from any cause (0.54 [CI, 0.35 to 0.82]) but had uncertain benefit for other outcomes; RRs were 0.63 (CI, 0.37 to 1.06) for ischemic stroke after 30 days, 0.90 (CI, 0.70 to 1.15) for mortality, and 0.90 (CI, 0.60 to 1.35) for HF hospitalization.
Limitations:
Clinical heterogeneity of trials, lack of participant-level data, and inclusion of unblinded trials.
Conclusion:
Catheter ablation reduced the risks for ischemic stroke at more than 30 days, mortality, and HF hospitalization. Surgical ablation had uncertain benefit, except for stroke.
Primary Funding Source:
National Center for Advancing Translational Sciences of the National Institutes of Health (Awards TL1TR002344 and UL1TR002345). (PROSPERO: CRD42023409751).
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:28Cardiac Catheterization I: Pre-Procedure Overview